Resources
12 Results (showing 1 - 10)
Results sorted by updated date (newest first)
Results sorted by updated date (newest first)
Posted 5/17/2021 (updated 4/10/2024)
New medications for office-based treatment of opioid
addiction are comparable in efficacy to other chronic
conditions such as diabetes, asthma, and hypertension
when combined with other interventions and as part of a
comprehensive care plan. They are safe, highly effective,
can be prescribed and/or administered at the Community
Health Center, with a sustainable business plan.
Posted 12/16/2020 (updated 4/4/2024)
As states seek new tools to meet the needs of individuals with substance use disorder (SUD) and opioid use disorder, federally qualified health centers (FQHCs) offer unique resources and examples for developing integrated and cost-effective health care services for complex and chronic conditions. The National Academy for State Health Policy developed this toolkit to share innovations, resources, and lessons learned from five state teams (AL, IL, SD, VA, and WI) that are working to strengthen the capacity of their FQHCs to deliver SUD care
Posted 11/24/2020 (updated 4/3/2024)
Join your HRSA project officers and JBS TELS as they cover: A review of selected focus areas and prevention, treatment and recovery Strategies chosen by grantees, Using the Collective Impact Approach to develop your consortium, Creating an effective Logic Model and Developing an effective Strategic Plan.
Posted 8/25/2021 (updated 4/2/2024)
HRSA’s Health Centers Program published new research briefs exploring health center capacity in maternity care deserts, differences in clinical quality measures among Appalachian and non-Appalachian health centers, and the role of health centers in providing medication-assisted treatment. The briefs were developed through the UDS Mapper—a tool that helps evaluate the geographic reach, penetration, and growth of the Health Center Program and its relationship to other federally-linked health resources.
Posted 7/28/2021 (updated 4/2/2024)
The most effective treatments for opioid use disorder (OUD) are the three prescription medications approved by the U.S. Food and Drug Administration (FDA)—methadone, buprenorphine, and naltrexone—that are proved to increase a patient’s treatment retention and reduce illicit use and the risk of overdose. The only facilities legally able to offer all three medications are opioid treatment programs (OTPs), a critical component of the U.S. substance use treatment system that are regulated by the federal Drug Enforcement Administration (DEA) and Substance Abuse and Mental Health Services Administration (SAMHSA), as well as state agencies, and are certified to administer any FDA-approved medication for the treatment of OUD.
Posted 12/31/2019 (updated 3/28/2024)
A Draft Working Document for the American Samoa Department of Human and Social Services’ Strategic Planning Initiative May 8-10, 2018. Adapted by JBS International for SAMHSA’ s State TA Project.
Posted 6/26/2020 (updated 3/28/2024)
The MAT for OUD Playbook aims to address the growing need for guidance as more primary care practices and health systems begin to implement MAT. The Playbook’s framework is designed to be useful for practices implementing any array of MAT services.
Posted 4/14/2020 (updated 3/28/2024)
Cross-sector collaboration between health and human services organizations is increasingly proposed as a promising strategy for addressing social determinants of health.
Posted 7/24/2020 (updated 3/28/2024)
The IHS forensic healthcare program was established in 2011 to address sexual violence, and has expanded to include intimate partner violence, child sexual abuse, and elder maltreatment. The program trains providers in forensic medical examinations, evidence collection techniques, and in coordinated community response to address violence.
Posted 11/11/2022 (updated 3/27/2024)
OMNI Institute, in partnership with the JBS RCORP-TA team, created the 2022-2023 RCORP-TA Data Learning Collaborative (LC) for grantees to come together and share knowledge, talk through challenges, and build relationships with one another. This LC will build upon the foundation established in the prior 2022 RCORP-TA Data Learning Collaborative.